WallStreetZenWallStreetZen

NYSE: TAK
Takeda Pharmaceutical Co Ltd Stock

$16.03-0.07 (-0.43%)
Updated Jan 27, 2023
TAK Price
$16.03
Fair Value Price
N/A
Market Cap
$53.42B
52 Week Low
$12.28
52 Week High
$16.30
P/E
22.8x
P/B
1.16x
P/S
1.32x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.30B
Earnings
$2.20B
Gross Margin
68.6%
Operating Margin
13.3%
Profit Margin
6.7%
Debt to Equity
1.17
Operating Cash Flow
$8B
Beta
0.55
Next Earnings
Feb 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

TAK Overview

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TAK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TAK is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TAK is good value based on its earnings relative to its share price (22.8x), compared to the US market average (23.59x)
P/E vs Market Valuation
TAK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more TAK due diligence checks available for Premium users.

Be the first to know about important TAK news, forecast changes, insider trades & much more!

TAK News

Valuation

TAK price to earnings (PE)

For valuing profitable companies with steady earnings
Company
22.8x
Industry
20.07x
Market
23.59x
TAK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TAK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

TAK price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.16x
Industry
1.9x
TAK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TAK's financial health

Profit margin

Revenue
$13.7B
Net Income
$1.2B
Profit Margin
8.4%
TAK's Earnings (EBIT) of $4.30B... subscribe to Premium to read more.
Interest Coverage Financials
TAK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$101.0B
Liabilities
$54.5B
Debt to equity
1.17
TAK's short-term assets ($18.78B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TAK's long-term liabilities ($37.51B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TAK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$2.1B
Investing
-$188.3M
Financing
-$359.0M
TAK's operating cash flow ($8.24B)... subscribe to Premium to read more.
Debt Coverage Financials

TAK vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
TAK$53.42B-0.43%22.80x1.16x
ZTS$76.99B-1.82%37.63x16.51x
VTRS$14.42B+2.15%18.02x0.75x
TEVA$11.53B+1.07%-8.95x1.31x
CTLT$9.66B+2.64%22.83x2.05x

Takeda Pharmaceutical Co Stock FAQ

What is Takeda Pharmaceutical Co's quote symbol?

NYSE: TAK) Takeda Pharmaceutical Co trades on the NYSE under the ticker symbol TAK. Takeda Pharmaceutical Co stock quotes can also be displayed as NYSE: TAK.

If you're new to stock investing, here's how to buy Takeda Pharmaceutical Co stock.

What is the 52 week high and low for Takeda Pharmaceutical Co (NYSE: TAK)?

(NYSE: TAK) Takeda Pharmaceutical Co's 52-week high was $16.30, and its 52-week low was $12.28. It is currently -1.66% from its 52-week high and 30.54% from its 52-week low.

How much is Takeda Pharmaceutical Co stock worth today?

(NYSE: TAK) Takeda Pharmaceutical Co currently has 1,666,098,437 outstanding shares. With Takeda Pharmaceutical Co stock trading at $16.03 per share, the total value of Takeda Pharmaceutical Co stock (market capitalization) is $53.42B.

Takeda Pharmaceutical Co stock was originally listed at a price of $21.37 in Jan 5, 2010. If you had invested in Takeda Pharmaceutical Co stock at $21.37, your return over the last 13 years would have been -24.99%, for an annualized return of -2.19% (not including any dividends or dividend reinvestments).

How much is Takeda Pharmaceutical Co's stock price per share?

(NYSE: TAK) Takeda Pharmaceutical Co stock price per share is $16.03 today (as of Jan 27, 2023).

What is Takeda Pharmaceutical Co's Market Cap?

(NYSE: TAK) Takeda Pharmaceutical Co's market cap is $53.42B, as of Jan 28, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Takeda Pharmaceutical Co's market cap is calculated by multiplying TAK's current stock price of $16.03 by TAK's total outstanding shares of 1,666,098,437.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.